What is a major outcome associated with SGLT2 inhibitors in heart failure?

What is a major outcome associated with SGLT2 inhibitors in heart failure?

• A. Reduced hospitalization for heart failure
• B. Worsened blood glucose
• C. Increased blood pressure
• D. No effect on outcomes

Answer: (A)

SGLT2 inhibitors provide meaningful cardiovascular benefits in heart failure, with the most consistent and clinically important outcome being a reduction in hospitalization for heart failure. Large trials showed that adding an SGLT2 inhibitor to standard therapy lowers the risk of hospital admissions for heart failure, and often also lowers the combined risk of cardiovascular death or HF hospitalization. This benefit appears in patients with reduced ejection fraction and extends to preserved ejection fraction as well, and it occurs regardless of whether the patient has diabetes. Mechanistically, these drugs promote glucosuria, which leads to osmotic diuresis and natriuresis. That helps reduce fluid overload and venous pressures, alleviating congestion and the need for hospital-level care. They also confer renal protective effects and may improve myocardial energy use and inflammation. While they do lower blood glucose in diabetics, the heart-failure benefits are not solely due to glycemic effects, which is why the HF outcome stands out as the major, well-supported benefit. Worsening blood glucose or increasing blood pressure would not describe the typical effects observed with these medications. In fact, blood pressure often decreases modestly due to the diuretic effect, and glycemic control tends to improve or stay stable in many patients. No effect on outcomes is not accurate given the clear reductions in HF hospitalizations seen in trials.

SGLT2 inhibitors provide meaningful cardiovascular benefits in heart failure, with the most consistent and clinically important outcome being a reduction in hospitalization for heart failure. Large trials showed that adding an SGLT2 inhibitor to standard therapy lowers the risk of hospital admissions for heart failure, and often also lowers the combined risk of cardiovascular death or HF hospitalization. This benefit appears in patients with reduced ejection fraction and extends to preserved ejection fraction as well, and it occurs regardless of whether the patient has diabetes.

Mechanistically, these drugs promote glucosuria, which leads to osmotic diuresis and natriuresis. That helps reduce fluid overload and venous pressures, alleviating congestion and the need for hospital-level care. They also confer renal protective effects and may improve myocardial energy use and inflammation. While they do lower blood glucose in diabetics, the heart-failure benefits are not solely due to glycemic effects, which is why the HF outcome stands out as the major, well-supported benefit.

Worsening blood glucose or increasing blood pressure would not describe the typical effects observed with these medications. In fact, blood pressure often decreases modestly due to the diuretic effect, and glycemic control tends to improve or stay stable in many patients. No effect on outcomes is not accurate given the clear reductions in HF hospitalizations seen in trials.